By Kamal Choudhury Jan 30 (Reuters) - Shares of Corcept Therapeutics fell 16% on Friday after a corrected "complete response ...
Stocktwits on MSN
CORT shares plummet on FDA’s drug rejection letter reveal — here’s what retail has to say
FDA refused to approve Corcept’s Relacorilant for hypercortisolism in December, citing insufficient proof of effectiveness.
On Jan. 30, 2026, Reuters reported that the FDA had issued a corrected CRL dated Jan. 28, 2026, which disclosed that the agency had warned Corcept "on several occasions" not to submit its relacorilant ...
We recently published 10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Hit Highs. Corcept Therapeutics Inc.
Corcept stock rises after a Phase 3 ovarian cancer trial showed longer survival and lower death risk, even as relacorilant ...
Corcept Therapeutics (CORT) shares soared 13.6% in the last trading session to close at $69.90. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter ("CRL" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results